You deserve tomorrow.

US Facilities

Pharmaceutical drug product development, analytical testing and CTM manufacturing all under one roof.

The US location currently occupies a state-of-the-art, fully qualified cGMP facility totaling nearly 8,650 m2 (93,000 sq ft). Located in Greenville, North Carolina, near the Research Triangle Park, a growing hub for pharmaceutical research activities in the US.

Today, our development and manufacturing space offers the following benefits:

  • A dedicated and segregated potent and cytotoxic facility
  • DEA-approved for Schedule II-V controlled substances
  • Stability studies, methods development and validation, raw materials, trace metals and microbiology laboratories
  • Drug product development and clinical trial manufacturing area
  • Manufacturing and packaging area for Phase III clinical trial materials and commercial manufacturing

 US Facilities

 US Facilities Expansion

US Facility expansion and renovation will deliver a 'Concept to Commercialization' solution for clients. 

Mayne Pharma is investing $65 million to expand facilities and equipment at their site in Greenville, N.C.

The $65 million strategic investment will fund:

  • A new 11,700 m2 (126,000-sq-ft), large-scale oral-dose commercial manufacturing facility
  • Expansion of contract analytical laboratory, formulation development and services capacity
  • A new visitor and staff administrative center

This means we can offer clients a comprehensive concept-to-commercialization solution in a single, contiguous site.

Other benefits of the expanded and improved facilities include:

  • Increased capacity in formulation development and analytical services
  • Engineered solutions to mitigate cross-contamination risks and support the handling of highly potent compounds
  • Expanded modified release platform
  • Planned solvent-capable fluid bed processing and film coating
  • Designed to serve international markets